Recent advances in genetic science are shifting colorectal cancer screening toward direct detection of DNA changes. In India, CRC is now the fourth most common cancer, with more than 64,000 new cases and over 38,000 deaths reported in 2022.
The liposomal doxorubicin market is projected to grow from $1.32 billion in 2025 to $1.77 billion by 2030, while the broader breast cancer drugs market is expected to reach $54.49 billion by 2036. Growth is driven by increasing cancer incidence, adoption of targeted therapies, and advancements in drug delivery systems including liposomal formulations and antibody-drug conjugates.
The phase 3 ENVISION trial shows 80% complete response rate for novel bladder cancer chemoablative therapy. AI integration accelerates precision oncology through biomarker identification and targeted treatments. OncoPRO real-time symptom monitoring system enhances patient safety and clinical trial data capture.
The global oncology precision medicine market is projected to grow from $190.50 billion in 2026 to $366.53 billion by 2033 at a 9.8% CAGR, while the cancer biomarker testing market is expected to reach $96.53 billion by 2033 at a 12.6% CAGR.
Precision oncology has transformed brain metastases treatment from lung cancer, extending survival from 6-12 months to 3-5 years through targeted therapies, immunotherapy, and radiosurgery. With 100,000-200,000 annual cases in the US, multidisciplinary approaches now manage this once-terminal condition as a chronic disease.
